Ixekizumab (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- TALTZ
Contraindications
TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients [see Warnings and Precautions (5.3)].
Adverse Reactions
The following adverse drug reactions are discussed in greater detail in other sections of the label: Infections [see Warnings and Precautions (5.1)] Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.3)] Eczematous Eruptions [see Warnings and Precautions (5.4)] Inflammatory Bowel Disease [see Warnings and Precautions (5.5)]
Mechanism of Action
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.